Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.51 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6545015 | 1.00 | TSHR (0.62) | TSHRLMNAALDH1A1SIGMAR1LOXL2 | |
| Hydrochloric Acid SCHEMBL1169677 | 0.98 | TSHR (0.61) | TSHRLMNAALDH1A1SIGMAR1LOXL2 | |
| Oxalic Acid SCHEMBL7219123 | 0.92 | TSHR (0.54) | TSHRLMNAALDH1A1SIGMAR1CYP2D6 | |
| Oxalic Acid SCHEMBL7219128 | 0.92 | TSHR (0.54) | TSHRLMNAALDH1A1SIGMAR1CYP2D6 | |
| SCHEMBL6998770 | 0.89 | TSHR (0.59) | TSHRLMNAALDH1A1SIGMAR1LOXL2 | |
| SCHEMBL1816182 | 0.85 | TSHR (0.62) | TSHRLMNAALDH1A1SIGMAR1CYP1A2 | |
| SCHEMBL43922 | 0.85 | TSHR (0.67) | TSHRLMNAALDH1A1LOXL2CYP1A2 | |
| SCHEMBL30504205 | 0.85 | TSHR (0.67) | TSHRLMNAALDH1A1LOXL2CYP1A2 | |
| Hydrochloric Acid SCHEMBL1017929 | 0.83 | TSHR (0.65) | TSHRLMNAALDH1A1LOXL2CYP1A2 | |
| SCHEMBL7399400 | 0.83 | TSHR (0.65) | TSHRLMNAALDH1A1SIGMAR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117510429-A | Compound containing methyl isoxazole structure, and preparation method and application thereof | 中国农业大学 | 2024-02-06 | — | — | CN | claimed |
| EP-4610262-A1 | MACROCYCLIC COMPOUND AS CDK9 INHIBITOR AND USE THEREOF | Artivila Biopharma (CN) | 2025-09-03 | — | — | EP | disclosed |
| CN-114685473-B | 5-Alkyl-2-pyrazole-oxazolidine-4-ketone derivative and application thereof | 杭州百新生物医药科技有限公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-117510429-A | Compound containing methyl isoxazole structure, and preparation method and application thereof | 中国农业大学 | 2024-02-06 | — | — | CN | disclosed |
| CN-112630347-B | HPLC analysis method for 4-nitrophenethylamine | 杭州华东医药集团浙江华义制药有限公司 | 2023-06-23 | — | — | CN | disclosed |
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2023-06-15 | — | — | US | disclosed |
| WO-2023081230-A1 | NOVEL AURISTATIN ANALOGS AND IMMUNOCONJUGATES THEREOF | ADCENTRX THERAPEUTICS INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20230109104-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | NUVATION BIO INC (US) | 2023-04-06 | — | — | US | disclosed |
| CN-114685473-A | 5-alkyl-2-pyrazole-oxazolidine-4-ketone derivative and application thereof | 杭州百新生物医药科技有限公司 | 2022-07-01 | — | — | CN | disclosed |
| WO-2022135601-A1 | 5-ALKYL-2-PYRAZOLE-OXAZOLIDINE-4-KETONE DERIVATIVE AND USE THEREOF | 杭州百新生物医药科技有限公司 | 2022-06-30 | — | — | WO | disclosed |
| EP-0671928-A4 | SYNTHESIS OF N-SUBSTITUTED OLIGOMERS. | CHIRON CORP (US) | 1997-04-23 | — | — | EP | disclosed |
| WO-1996040202-A1 | SYNTHESIS OF N-SUBSTITUTED OLIGOMERS | CHIRON CORPORATION (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5536853-A | Opiate receptor ligands | CHIRON CORPORATION (US) | 1996-07-16 | — | — | US | disclosed |
| US-5480871-A | TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | CHIRON CORPORATION (US) | 1996-01-02 | — | — | US | disclosed |
| WO-1995027729-A1 | OPIATE RECEPTOR LIGANDS | CHIRON CORPORATION (US) | 1995-10-19 | — | — | WO | disclosed |
| EP-0671928-A1 | SYNTHESIS OF N-SUBSTITUTED OLIGOMERS | CHIRON CORPORATION (US) | 1995-09-20 | — | — | EP | disclosed |
| US-5447916-A | Hypotensive agents | CHIRON CORPORATION (US) | 1995-09-05 | — | — | US | disclosed |
| WO-1995004072-A1 | PEPTOID ALPHA-1 ADRENERGIC RECEPTOR LIGANDS | CHIRON CORPORATION (US) | 1995-02-09 | — | — | WO | disclosed |
| EP-0614898-A1 | INDOLE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 1994-09-14 | — | — | EP | disclosed |
| WO-1994006451-A1 | SYNTHESIS OF N-SUBSTITUTED OLIGOMERS | CHIRON CORPORATION (US) | 1994-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230109104-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, NME1 | TSHR 4456/4885LMNA 3549/4885ALDH1A1 2869/4885 |
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, STING1 | TSHR 2936/4885LMNA 3502/4885ALDH1A1 1769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.